MetLife Investment Management’s Pliant Therapeutics PLRX Stock Holding History

MetLife Investment Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-36,788	Closed	-$484K	–	2817
2024 Q4	$484K	Buy	36,788 +3,925	+12%	+$53.6K	﹤0.01%	1819
2024 Q3	$368K	Hold	32,863	–	–	﹤0.01%	1953
2024 Q2	$353K	Buy	32,863 +3,049	+10%	+$39.3K	﹤0.01%	1919
2024 Q1	$444K	Hold	29,814	–	–	﹤0.01%	1740
2023 Q4	$540K	Hold	29,814	–	–	﹤0.01%	1641
2023 Q3	$517K	Hold	29,814	–	–	﹤0.01%	1613
2023 Q2	$540K	Buy	+29,814	New	+$706K	﹤0.01%	1647
2022 Q1	–	Sell	-9,508	Closed	-$128K	–	2760
2021 Q4	$128K	Hold	9,508	–	–	﹤0.01%	2311
2021 Q3	$160K	Hold	9,508	–	–	﹤0.01%	2218
2021 Q2	$277K	Hold	9,508	–	–	﹤0.01%	1941
2021 Q1	$374K	Buy	9,508 +4,633	+95%	+$150K	﹤0.01%	1690
2020 Q4	$111K	Hold	4,875	–	–	﹤0.01%	2218
2020 Q3	$110K	Buy	+4,875	New	+$122K	﹤0.01%	2169

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

MetLife Investment Management's PLRX Position: Q1 2025 in Review

MetLife Investment Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 36,788 shares — an estimated $484K sold.

MetLife Investment Management first reported a position in PLRX in Q3 2020 and held it in 13 quarters. The position peaked at $540K in Q2 2023. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

MetLife Investment Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
MetLife Investment Management sold 36,788 Pliant Therapeutics shares in Q1 2025, an estimated $484K.
MetLife Investment Management first reported a position in Pliant Therapeutics in Q3 2020 and held it in 13 quarters.
MetLife Investment Management's Pliant Therapeutics position peaked at $540K in Q2 2023.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.